International Conference World of Healthcare 28th of September 2017 The Hague.

Portavita Solution

Portavita, offers a next-generation Health Management Platform supporting individualised care and collaboration in the region and facilitates management of patient populations. Besides the treatment support for Diabetes, Cardio Vascular Risk-Management, Asthma/COPD and Elderly care, we have gained worldwide experience for over 15 years with our Anticoagulation software.

Via these links you will find more specific information regarding the following treatments: Anticoagulation, Asthma/COPD, Cardiovascular Risk Management, Diabetes and Elderly Care.

Evidence

Portavita solutions support thousands of medical organizations since 2002. Currently our Dutch, German, Russian and South American customers support over 500.000 patients. They work in a multi-organizational and multi-disciplinary setting. Within these healthcare organizations, 10.000 medical professionals and over 100.000 participating self-management patients use our online solution on a daily basis. These organizations achieve over 80% of patients, treated with Oral AC, to be in their therapeutic range (TTR). In most countries this is on average 10% lower. Many countries are performing even seriously lower at higher cost per monitored patient.

Partner

Amongst others our partners are VU Medical Centre, Philips Healthcare, Roche Diagnostics and Deutsche Telekom Health Solutions.

Research & Innovation

• thrombEVAL
  A project to research the applicability of the Dutch based anticoagulation solution for Germany. Munzel T, Wild PS. Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service – results from the prospective, multi-center, observational cohort study thrombEVAL. European Journal of Preventive Cardiology, 2014.
• Near Patient Testing by care takers in elderly homes
  Study into the effectiveness, safety and well-considered introduction of Near-Patient Testing in elderly and nursing homes in The Netherlands. Verstappen WHJM, Land RP van ‘t.Near-Patient Testing (NPT) of coagulation time in health care institutions.
• Oral anticoagulants for stroke prevention in non-valvular atrial fibrillation. Prof. Michael Barry, Clinical Lead, MMP.

Quality and privacy

• Portavita is ISO 13485:2003 certified since 22 January 2014.
• Portavita is compliant with the European medical device directive 93/42/EEC (CE label)
• Portavita complies with the Dutch and German Personal Data Protection Acts.
• For the Russian market we have a Roszdravnazor registration certificate.

Business Model

Together with our local partner we organize a total solution, including medical care providers responsible for the treatment, devices, medication, reimbursement, Standard Operation Procedures, education and ICT. Portavita offers its platform on a “pay per use” basis. One-time investments are related to translation, local hosting, training and potential adaption to the local protocols.

We look for Partners

Do you see an opportunity for improved patient treatment, a business case, using the Portavita Integrated Care System? Our Platform can be an add-on for applications that you already use, or it might offer you the possibility to collaborate on a specific clinical picture. Or perhaps it could support you in the improvement of the treatment of patients who live in rural areas. Just feel free to contact us to discuss how we can help realize your goals.

Portavita

Evert Jan Hoijtink Founder & CEO
Oostenburgervoorstraat 83a
1018MP Amsterdam
The Netherlands
+31 652 523 541 [mobile]
e.j.hoijtink@portavita.eu
www.portavita.com